Citius Pharmaceuticals, Inc. — Income Charts
62 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$4M
Cost of Revenue
$789K
Gross Profit
$3M
R&D↓-24.8% -$527K
$2M
D&A↓-100.0% -$578
$0
Operating Income↑+10.2% +$1M
$-9M
EBITDA↑+10.2% +$1M
$-9M
Interest Expense
$156K
Interest Income↑+99.5% +$22K
$45K
Other Income/Expense
$0
Pretax Income↑+8.9% +$887K
$-9M
Tax Provision↑+0.0% +$0
$264K
Net Income↑+8.6% +$887K
$-9M
Gross Margin
80.0%
Operating Margin
-228.7%
Net Margin
-238.2%
Effective Tax Rate↓-0.3pts
-2.9%
Deferred Tax Liabilities↑+15.1% +$1M
$8M
ETR (Continuing Operations)↑+1.2pts
2.7%
ETR State + Local (pp)↑+0.0pts
-6.3%
ETR Foreign Differential (pp)↓-1.5pts
4.0%
Operating Lease Cost↓-39.6% -$24K
$36K
Revenue YoY Variation↓-100.0pts
-100.0%
Income YoY Variation↑+1.7pts
10.2%
Revenue QoQ Variation↑+233.3pts
166.7%
Income QoQ Variation
22.0%